Botulinum toxin type a for alopecia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jul 2022: Trial registered, NCT05456087
  2. 12 Aug 2022: Trial started, NCT05456087

The trials

NCT05456087: Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

State
Under way
Phase
Phase 2
People
20 taking part
Started
12 Aug 2022
Primary completion
Dec 2024
Arms
Single treatment with Xeomin® (incobotulinumtoxin A)
Results
None posted
  1. 13 Jul 2022: Trial registered
  2. 12 Aug 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as AGN-151607-DP, Bocouture, Botox 50 Unit Injection, Botulinum toxin A, Xeomin, incobotulinumtoxin A.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.